3-Methylhistidine
|
Basic information |
| Metabolite name | 3-Methylhistidine |
 | HMDB0000479 |
 |
C01152 |
 |
64969 |
| Synonyms | 3-Methyl-L-histidine; |
| No. of studies | 12 |
|
Basic information |
| Metabolite name | 3-Methylhistidine |
| HMDB0000479 |
|
C01152 |
|
64969 |
| Synonyms | 3-Methyl-L-histidine; |
| No. of studies | 12 |
|
Relationship between 3-Methylhistidine and depression (count: 12) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1055 | Type1 | depression group vs. control group | Urine | Human | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M474 | Type1 | rTMS-treated olfactory bulbectomy group vs. sham-treated olfactory bulbectomy group | Plasma | C57BL/6J mouse | Down |
| Study M474 | Type1 | olfactory bulbectomy group vs. control group | Plasma | C57BL/6J mouse | Up |
| Study M544 | Type1 | PSD group vs. stoke group | Plasma | Human | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Urine | Human | Unknown |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Medial prefrontal cortex | C57BL/6 J mouse | Up |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Up |
| Study M827 | Type1 | CUMS + low dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M827 | Type1 | CUMS + middle dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M827 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M827 | Type1 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M827 | Type1 | CUMS + high dose of Millettia speciosa Champ group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M916 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |